Company news
Quince Therapeutics, Inc. news in 2025
Quince Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
December 15, 2025
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
December 10, 2025
Quince Therapeutics to Participate at Investor Events in December 2025
November 24, 2025
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
November 10, 2025
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
October 9, 2025
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
September 25, 2025
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
September 11, 2025
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 11, 2025
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
August 7, 2025
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
July 16, 2025
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
July 10, 2025
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
June 25, 2025
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
June 18, 2025
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
June 12, 2025
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
June 3, 2025
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
May 13, 2025
Quince Therapeutics to Present at Citizens Life Sciences Conference
April 30, 2025
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
April 3, 2025
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
March 24, 2025
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
February 3, 2025
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
January 26, 2025
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
January 22, 2025